Breaking record! Hengrui Medicine's 2025 interim report: net profit of 4.45 billion yuan, up 29.67%

On August 20th, Hengrui Medicine released its 2025 semi-annual report. The report shows that in the first half of 2025, the company achieved operating income of 15.761 billion yuan, a year-on-year increase of 15.88%; net profit attributable to shareholders of the listed company reached 4.45 billion yuan, a year-on-year increase of 29.67%; and net operating cash flow was 4.3 billion yuan, a year-on-year increase of 41.80%. Both revenue, net profit, and net operating cash flow hit new highs compared to the same period in previous years, and the performance has entered a period of explosive growth. The company continues to increase its innovation efforts and maintain a high level of research and development investment. During the reporting period, the company invested 3.871 billion yuan in research and development, with 3.228 billion yuan in expenses for research and development.